Regulatory Filings • Feb 10, 2011
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 10 February 2011 07:00
Cytos Biotechnology Presents Latest Data on the Mechanism of Action of QbG10 for the Treatment of Allergic Asthma at the 3rd International Conference on Drug Discovery and Therapy
Cytos Biotechnology AG / Key word(s): Research Update
10.02.2011 / 07:00
Schlieren (Zurich), Switzerland, February 10, 2011 – Cytos Biotechnology Ltd (SIX:CYTN) today announced that PD Dr. Martin Bachmann, CSO of Cytos, will present latest data on the mechanism of action of CYT003-QbG10 (QbG10), a safe and efficacious drug candidate for the treatment of allergic asthma and rhinitis, at the 3rd International Conference on Drug Discovery and Therapy in Dubai.
QbG10 is a Toll-like receptor 9 agonist with clinical proof-of-concept in allergic asthma and rhinitis. Allergic Asthma is a disease primarily mediated by type 2 T helper cells (Th2). Th2 cells influence the asthmatic response by secreting substances which recruit inflammatory cells into the lungs, increase mucus production in the airways and cause airway hyper-reactivity. The resultant obstruction of the airways is the most critical aspect of asthma. Therefore, blocking Th2 cells is an important goal for the treatment of asthma. Researchers from Cytos Biotechnology have now identified two ways by which the Toll-like receptor 9 agonist QbG10 blocks Th2 responses. Firstly, QbG10 induces interferon alpha, a factor that directly inhibits Th2 cells. Secondly they showed QbG10 induces ICOS ligand, a protein which causes generation of a special subset of anti-inflammatory T cells called regulatory T cells. Such regulatory T cells are known to be capable of blocking Th2 cell activity. Hence, QbG10 controls asthma by directly inhibiting Th2 responses and by fostering the generation of regulatory T cells.
Dr Martin Bachmann, CSO of Cytos Biotechnology commented: 'These new data provide an explanation of the mechanism of action of QbG10. This finding is not only important for the further development and registration of this new therapeutic modality but it will possibly also shed light on the etiology of this widespread disease.'
For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: [email protected]
Website: www.cytos.com
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug(TM) platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug(TM) candidates in various disease areas, of which five are currently in clinical development. The Immunodrug(TM) candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 77 full-time equivalents. Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that include words or phrases such as 'will', 'designed', 'intended' or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.
End of Corporate News
10.02.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Schweiz | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Swiss Security Number: | – |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt |
| End of News | EquityStory AG News-Service |
| - - - |
| 111632 10.02.2011 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.